VIDA Insights

VIDA
VIDA Insights™ is a lung intelligence solution providing quantitative data and visualizations. VIDA’s biomarkers measure lung destruction, inflammation, function and more, to aid the detection, diagnosis, treatment and tracking of all major lung diseases, including COPD, ILD and now COVID-19.
Information source: Vendor
Last updated: Feb. 28, 2020

General Information

General
Product name VIDA Insights
Company VIDA
Subspeciality Chest
Modality CT
Disease targeted COPD, interstitial lung disease (ILD), emphysema, COVID-19
Key-features Lung disease biomarkers, lung (lobe) volume quantification, scan suitability quality check, Hyperion View (tMPR), low density tissue quantification by lobe, high density tissue quantification by lobe, trachea analysis and quanitification
Suggested use Before: stratifying reading process (non, single, double read)
During: perception aid (prompting all abnormalities/results/heatmaps), report suggestion

Technical Specifications

Data characteristics
Population All Chest CT scans
Input Non-contrast
Input format DICOM
Output Quantified Values, Novel Visualizations, Quick Flag Diagrams
Output format DICOM SC
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis Automatically, right after the image acquisition
Processing time 1 - 10 minutes

Regulatory

Certification
CE
Certified, Class IIa , MDD
FDA 510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE) The design and manufacture of post processing software utilised in the diagnosis and documentation of pulmonary and smoking related diseases via datasets acquired from various medical modalities.

Market

Market presence
On market since 12-2019
Distribution channels Nuance PIN, Eureka Clinical AI, TeraRecon, IBM Watson Health, Blackford, Intelerad, Calantic
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model Subscription
Based on Total imaging volume

Evidence

Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers

  • Relationships Between Airflow Obstruction and Quantitative CT Measurements of Emphysema, Air Trapping, and Airways in Subjects With and Without Chronic Obstructive Pulmonary Disease (read)

  • Quantitative computed tomography of the lungs and airways in healthy nonsmoking adults (read)

  • Total Airway Count on Computed Tomography and the Risk of Chronic Obstructive Pulmonary Disease Progression. Findings from a Population-based Study (read)

  • Quantitative CT of Interstitial Lung Disease (read)

  • SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs (read)